Navigation Links
Affymax(R) and Takeda Recognized for Innovative Global Agreement to Develop and Commercialize Hematide(TM) for Anemia
Date:10/17/2007

PALO ALTO, Calif. and OSAKA, Japan, Oct. 17 /PRNewswire/ -- Affymax, Inc. (Nasdaq: AFFY) and Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that they have been awarded the 2007 Deal of Distinction Award from the Licensing Executives Society of the U.S. and Canada (LES) for their innovative global agreement to develop and commercialize Affymax's lead product candidate, Hematide(TM), for the treatment of anemia. The Affymax and Takeda collaboration was recognized by the LES as one of the most notable deals in the healthcare industry sector in the last year.

The 2007 Deal of Distinction Award recognizes worthy transactions involving the transfer and licensing of intellectual property using creative and innovative solutions to business issues. This year, the award was given to parties of only five deals.

"We are pleased to have received this award, which recognizes our strategic alliance with Takeda to develop Hematide worldwide as a potential treatment for anemia associated with chronic renal failure and cancer," said Arlene M. Morris, Affymax's president and chief executive officer. "Affymax and Takeda have made significant progress in the Hematide clinical development program. We recently initiated a Phase 3 clinical program for Hematide, and we look forward to continuing our progress to develop a new treatment option that addresses anemia in chronic renal failure patients."

"We are very pleased that Takeda's partnership with Affymax for Hematide is being recognized by esteemed licensing professionals," said Yasuchika Hasegawa, president, Takeda Pharmaceutical Company Limited. "The collaboration on this potential new entrant to the worldwide anemia market represents an important component of our global growth strategy. We look forward to continued progress in the Hematide clinical development program."

Affymax and Takeda are collaborating on the development of Hematide and will co-commercialize the product in the United States. Takeda has been granted an exclusive, royalty-bearing license to develop and commercialize Hematide outside the United States, including Japan. Under the terms of the collaboration, Affymax received $132 million in upfront and milestone payments and $10 million from the sale of equity. Affymax is eligible to receive development and regulatory milestone payments of up to an additional $345 million and commercial milestone payments upon successful commercialization of Hematide of up to $150 million.

About Hematide

Hematide is a novel synthetic, pegylated peptidic compound that binds to and activates the erythropoietin receptor and thus acts as an erythropoiesis stimulating agent. The investigational product is being developed for the treatment of anemia in patients with chronic renal failure (CRF) and cancer patients receiving chemotherapy.

About Affymax, Inc.

Affymax, Inc. is a biopharmaceutical company developing novel drugs to improve the treatment of serious and often life-threatening conditions. Affymax's lead product candidate, Hematide(TM), is currently in Phase 3 clinical trial stage for the treatment of anemia associated with chronic renal failure and in clinical trials for the treatment of anemia in cancer patients. For additional information, please visit http://www.affymax.com.

About Takeda

Located in Osaka, Japan, Takeda (TSE: 4502) is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate website, http://www.takeda.com.

This release contains forward-looking statements, including statements regarding the timing, design and results of the Company's clinical trials and drug development program and the timing and likelihood of the commercialization of Hematide. The Company's actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties, including risks relating to the continued safety and efficacy of Hematide in clinical development, the potential for once per month dosing, regulatory requirements and approvals, research and development efforts, industry and competitive environment, intellectual property rights and disputes and other matters that are described in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement in this press release.


'/>"/>
SOURCE Takeda Pharmaceutical Company Limited
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. UWM recognized for info-sharing software
2. Neurognostics recognized for MRI award
3. Wisconsin scientists to be recognized for innovative biofuel technology
4. nPoint recognized as small company of year by MIT Club of Wisconsin
5. Wisconsins biotech industry recognized by national publication
6. Innovative Tissue Array Technology for High-Throughput Screening of Gene Expression
7. HotMasterAn innovative Hot Start/Cold Stop technology for better PCR* results
8. Hewlett-Packard exec offers innovative counsel
9. Cisco names Inacom most innovative partner
10. Innovative health care takes more than just IT automation
11. Innovative Health Strategies near Milwaukee set to profit from Medicare expansion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... ... scaffold technology, today announced the election of Paul Hermes, Entrepreneur in Residence at ... , Biorez has developed a proprietary, tissue-engineered scaffold for anterior cruciate ligament ...
(Date:9/20/2017)... ... September 20, 2017 , ... Proscia Inc. , ... a provider of whole slide imaging solutions, are hosting a pre-conference workshop at ... “Successfully Deploying a Best-in-Class Strategy for Digital Pathology,” will feature Proscia CEO, David ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... the most dangerous step of sample prep for metals digestion—the addition of acids ... at an affordable price. The system is ideal for any laboratory performing their ...
(Date:9/19/2017)... ... September 19, 2017 , ... One of ... to be eliminated, said Lyle Probst, President, CEO and Founder of ExcitePCR ... than other pathogen detection solutions, Probst said, “Sample preparation takes place inside our ...
Breaking Biology Technology:
(Date:8/23/2017)... , Aug. 23, 2017  The general public,s help is being ... microbiome—the bacteria that live in and on the human body –and are ... The Microbiome ... the human microbiome, starting with the gut. The project's goal is to ... Photo credit: IBM ...
(Date:8/15/2017)... 15 2017   ivWatch LLC , a medical device company ... today announced receipt of its ISO 13485 Certification, the global standard ... Organization for Standardization (ISO®). ... Model 400 Continuous Monitoring device for the early detection of IV ... "This is an important milestone for ...
(Date:7/20/2017)... 20, 2017 Delta (NYSE: DAL ) customers now ... aircraft at Reagan Washington National Airport (DCA). ... Delta launches biometrics to board aircraft at ... Delta,s biometric boarding pass experience ... is now integrated into the boarding process to allow eligible Delta SkyMiles ...
Breaking Biology News(10 mins):